

Cover Story
Free
By Matthew Bin Han Ong
Women who were subjected to minimally invasive surgery for early-stage cervical cancer were four times more likely to die from that disease within three years, three times more likely to have a recurrence within three years, and had shorter overall survival, compared to women who underwent open surgery, according to two groundbreaking studies published in The New England Journal of Medicine Oct. 31.
In Brief


Funding Opportunities
Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for November
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Daraxonrasib’s success in treating pancreatic cancer is a reminder that clinical cancer researchers are heroes
- Pam Bondi diagnosed with thyroid cancer
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
















